Genomic Health Awarded New Patents Covering Oncotype DX Technology; Reports Revenue Growth in Q2 | GenomeWeb

By Turna Ray

Genomic Health has been granted two new US patents for its Oncotype DX breast cancer test, the company announced this week during its second quarter earnings call with investors.

According to the company, the patents cover "methods for the algorithms used and methods utilizing genes beyond the current 21 gene set."

Genomic Health has previously said it intends to expand the gene set interrogated by Oncotype DX as new research becomes available.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.